{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:21:07Z","timestamp":1778055667684,"version":"3.51.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate the clinical significance of volumetric parameters derived from\n                      <jats:sup>68<\/jats:sup>\n                      Ga-prostate-specific membrane antigen (PSMA) PET\/computed tomography (CT) for prostate cancer staging and their association with metastatic disease and tumor aggressiveness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 206 treatment-naive patients with newly diagnosed, histopathologically confirmed prostate cancer who underwent\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/CT for initial staging. Primary tumor maximum standardized uptake value (SUVmax), SUVmean, PSMA tumor volume (PSMA-TV), and total lesion PSMA (TL-PSMA) were measured using a semi-automatic segmentation method. Metastatic disease was defined by PSMA-avid nodal or distant lesions. Imaging parameters were correlated with serum prostate-specific antigen (PSA) levels, Gleason score, International Society of Urological Pathology (ISUP) grade, and D\u2019Amico risk classification. Diagnostic performance was assessed using receiver operating characteristic analysis, and independent predictors of metastasis were evaluated using multivariable logistic regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Metastatic disease was detected in 52 of 206 patients (25.2%). TL-PSMA showed the highest diagnostic performance for predicting metastasis [area under the curve (AUC)\u2005=\u20050.80], followed by PSA (AUC\u2005=\u20050.78) and PSMA-TV (AUC\u2005=\u20050.77), whereas SUV-based parameters demonstrated moderate accuracy (AUC\u2005=\u20050.74). In multivariable analysis, TL-PSMA and PSA remained independent predictors of metastatic disease (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.01). Volumetric and SUV-based PSMA parameters increased significantly with higher D\u2019Amico risk category, ISUP grade, and Gleason score (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.0001). Bilobar intraprostatic PSMA uptake was significantly associated with metastatic disease and high-risk pathological features (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Volumetric\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA PET\/CT parameters, particularly TL-PSMA, provide clinically relevant information for prostate cancer staging beyond conventional SUV metrics and PSA. Bilobar intraprostatic PSMA uptake is associated with aggressive disease and increased metastatic risk and may serve as a useful imaging marker in initial staging.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002136","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:01:44Z","timestamp":1773046904000},"page":"732-740","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of volumetric 68Ga-prostate-specific membrane antigen PET\/computed tomography parameters in prostate cancer staging"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7005-578X","authenticated-orcid":false,"given":"Yi\u011fithan","family":"Okar","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Umraniye Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcseyin","family":"Yel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Umraniye Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"R2-20260506","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis.","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"key":"R3-20260506","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.","volume":"1","author":"Wright","year":"1995","journal-title":"Urol Oncol"},{"key":"R4-20260506","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management.","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat Rev Urol"},{"key":"R5-20260506","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s12149-018-1277-5","article-title":"Prognostic value of 68 Ga PSMA I&T PET\/CT SUV parameters on survival outcome in advanced prostat cancer.","volume":"32","author":"Komek","year":"2018","journal-title":"Ann Nucl Med"},{"key":"R6-20260506","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"R7-20260506","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","article-title":"68Ga-PSMA PET\/CT detects the location and extent of primary prostate cancer.","volume":"57","author":"Fendler","year":"2016","journal-title":"J Nucl Med"},{"key":"R8-20260506","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"R9-20260506","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/MNM.0000000000001874","article-title":"Utility of PSMA-PET derived volumetric parameters in initial risk stratification and prediction of prostate cancer metastasis - a head-to-head comparison of the radiotracers 18 F-PSMA-1007 and 68 Ga-PSMA-11.","volume":"45","author":"Chandekar","year":"2024","journal-title":"Nucl Med Commun"},{"key":"R10-20260506","doi-asserted-by":"crossref","first-page":"1335205","DOI":"10.3389\/fonc.2024.1335205","article-title":"Predictive value of volumetric parameters based on 18F-PSMA-1007 PET\/CT for prostate cancer metastasis.","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"R11-20260506","doi-asserted-by":"crossref","first-page":"1025930","DOI":"10.3389\/fonc.2022.1025930","article-title":"18F-PSMA-1007 PET\/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer.","volume":"12","author":"Dong","year":"2022","journal-title":"Front Oncol"},{"key":"R12-20260506","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/cancers15041020","article-title":"Advanced PSMA-PET\/CT imaging parameters in newly diagnosed prostate cancer patients for predicting metastatic disease.","volume":"15","author":"Yechiel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R13-20260506","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent.","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"R14-20260506","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN guidelines insights: prostate cancer, version 1.2021.","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 1","key":"R15-20260506","doi-asserted-by":"crossref","first-page":"e586s","DOI":"10.6061\/clinics\/2018\/e586s","article-title":"Clinical perspectives of PSMA PET\/MRI for prostate cancer.","volume":"73","author":"Barbosa","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"R16-20260506","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s00330-014-3539-5","article-title":"Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.","volume":"25","author":"Vargas","year":"2015","journal-title":"Eur Radiol"},{"key":"R17-20260506","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.3390\/curroncol31090391","article-title":"The relationship between D\u2019Amico and ISUP risk classifications and 68Ga-PSMA PET\/CT SUVmax values in newly diagnosed prostate cancers.","volume":"31","author":"Ulas Babacan","year":"2024","journal-title":"Curr Oncol"},{"key":"R18-20260506","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:01:07Z","timestamp":1778054467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002136","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}